Detection of EPO-Fc fusion protein in human blood: Screening and confirmation protocols for sports drug testing

Drug Testing and Analysis

Volumn 4, Issue 11, 2012, Pages 818-829

  Reichel, Christian ^a,c   Thevis, Mario ^b,c  

^a AIT Seibersdorf Laboratories   (Austria)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

^c European Monitoring Center for Emerging Doping Agents   (Germany)

Author keywords

Doping control; EPO Fc; Erythropoietin; Fusion protein; IEF PAGE; Isoelectric focusing; Recombinant erythropoietin Fc chimera; SAR PAGE; SARCOSYL PAGE; SDS PAGE

Indexed keywords

BLOOD; CONTROLLED DRUG DELIVERY; ELECTROPHORESIS; RECOMBINANT PROTEINS; SODIUM DODECYL SULFATE; SULFUR COMPOUNDS;

DOPING CONTROL; EPO-FC; ERYTHROPOIETIN; FUSION PROTEINS; IEF-PAGE; ISOELECTRIC FOCUSING; RECOMBINANT ERYTHROPOIETIN FC CHIMERA; SAR-PAGE; SARCOSYL; SARCOSYL-PAGE; SDS-PAGE;

SPORTS;

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN A; PROTEIN G; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN IMMUNOGLOBULIN FC FRAGMENT; UNCLASSIFIED DRUG;

ARTICLE; ATHLETE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CONTROLLED STUDY; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; ISOELECTRIC FOCUSING; LIMIT OF DETECTION; MASS SPECTROMETRY; MOLECULAR WEIGHT; PLASMA HALF LIFE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; SARCOSYL POLYACRYLAMIDE GEL ELECTROPHORESIS; SENSITIVITY AND SPECIFICITY; SPORT; TWO DIMENSIONAL POLYACRYLAMIDE GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 84870246919     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.1381     Document Type: Article

References (56)

1. D.C. Roopenian, S. Akilesh FcRn: The neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7, 715.
2. B. Rubin, J.B. Fink, in The Pulmonary Epithelium in Health and Disease, (Ed: D. Proud ). Wiley, Chichester, 2008, pp. 411-427.
3. G.M. Spiekermann, P.W. Finn, E.S. Ward, J. Dumont, B.L. Dickinson, R.S. Blumberg, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J. Exp. Med. 2002, 196, 303.
4. F.K. Lin, S. Suggs, C.H. Lin, J.K. Browne, R. Smalling, J.C. Egrie, et al. Cloning and expression of the human erythropoietin gene. Proc. Natl. Acad. Sci. USA 1985, 82, 7580.
5. M.A. Foote, in Erythropoetins, Erythropoietic Factors, and Erythropoiesis, 2nd edition, (Eds: S.G. Elliott, M.A. Foote, G. Molineux ). Birkhäuser, Basel, 2009, pp. 77-85.
6. J.C. Egrie, J.K. Browne Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transpl. 2001, 16, 3.
7. I.C. Macdougall, R. Robson, S. Opatrna, X. Liogier, A. Pannier, P. Jordan, et al. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2006, 1, 1211.
8. C.H. Joung, J.Y. Shin, J.K. Koo, J.J. Lim, J.S. Wang, S.J. Lee, et al. Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell. Protein Expres. Purif. 2009, 68, 137.
9. A.J. Bitonti, J.A. Dumont, S.C. Low, R.T. Peters, K.E. Kropp, V.J. Palombella, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc. Natl. Acad. Sci. USA 2004, 101, 9763.
10. A.J. Bitonti, J.A. Dumont Pulmonary administration of therapeutic proteins using an immunoglobulin transport pathway. Adv. Drug Deliv. Rev. 2006, 58, 1106.
11. K. Schriebl, E. Trummer, C. Lattenmayer, R. Weik, R. Kunert, D. Muller, et al. Biochemical characterization of rhEpo-Fc fusion protein expressed in CHO cells. Protein Expres. Purif. 2006, 49, 265.
12. A. Coscarella, C. Carloni, R. Liddi, S. Mauro, S. Novelli, A. Mele, et al. Production of recombinant human GM-CSF-EPO hybrid proteins: In vitro biological characterization. Eur. J. Haematol. 1997, 59, 238.
13. I.C. Macdougall Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin. J. Am. Soc. Nephrol. 2008, 3, 200.
14. P.J. Carter Introduction to current and future protein therapeutics: A protein engineering perspective. Exp. Cell Res. 2011, 317, 1261.
15. J.C. Way, S. Lauder, B. Brunkhorst, S.M. Kong, A. Qi, G. Webster, et al. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond. Protein Eng. Des. Sel. 2005, 18, 111.
16. R. Siekmeier, G. Scheuch, in Applied Technologies in Pulmonary Medicine, (Ed: A. M. Esquinas ). Karger, Basel, 2011, pp. 67-76.
17. C. Lattenmayer, M. Loeschel, K. Schriebl, W. Steinfellner, T. Sterovsky, E. Trummer, et al. Protein-free transfection of CHO host cells with an IgG-fusion protein: Selection and characterization of stable high producers and comparison to conventionally transfected clones. Biotechnol. Bioeng. 2007, 96, 1118.
18. J.A. Dumont, S.C. Low, R.T. Peters, A.J. Bitonti, in Therapeutic Monoclonal Antibodies: From Bench to Clinic, (Ed: Z. An ). Wiley, Hoboken, 2009, pp. 779-795.
19. J.A. Dumont, S.C. Low, R.T. Peters, A.J. Bitonti Monomeric Fc fusions: Impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs. 2006, 20, 151.
20. J.A. Dumont, A.J. Bitonti, D. Clark, S. Evans, M. Pickford, S.P. Newman Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J. Aerosol Med. 2005, 18, 294.
21. World Anti-Doping Agency (WADA). Available at: http://www.wada-ama.org/Documents/World_Anti-Doping_Program/WADP-Prohibited-list/2012/WADA_Prohibited_List_2012_EN.pdf [6 January 2012].
22. UniProt database. Available at: http://www.uniprot.org/ [7 January 2012].
23. J.V. Olsen, L.M. de Godoy, G. Li, B. Macek, P. Mortensen, R. Pesch, et al. Parts per million mass accuracy on an Orbitrap mass spectrometer via lock mass injection into a C-trap. Mol. Cell. Proteomics 2005, 4, 2010.
24. E. Völker-Schänzer, B. Majer, R. Kempkes, P. Reihlen, A. Thomas, M. Thevis, et al. An efficient sample preparation for CERA analysis in serum (Poster presentation). 29th Cologne Workshop on Dope Analysis (13-18 February 2011), 2011.
25. MAIIA Diagnostics. EPO purification kit. Available at: http://www.maiiadiagnostics.com/files/Directions%20for%20Use%20-%20EPO%20Purification%20Kit%20v6.pdf [20 December 2011].
26. C. Reichel The overlooked difference between human endogenous and recombinant erythropoietins and its implication for sports drug testing and pharmaceutical drug design. Drug Test. Anal. 2011, 3, 883.
27. C. Reichel, F. Abzieher, T. Geisendorfer SARCOSYL-PAGE: A new method for the detection of MIRCERA- and EPO-doping in blood. Drug Test. Anal. 2009, 1, 494.
28. C. Reichel, R. Kulovics, V. Jordan, M. Watzinger, T. Geisendorfer SDS-PAGE of recombinant and endogenous erythropoietins: Benefits and limitations of the method for application in doping control. Drug Test. Anal. 2009, 1, 43.
29. C. Reichel Practicing IEF-PAGE of EPO: The impact of detergents and sample application methods on analytical performance in doping control. Drug Test. Anal. 2010, 2, 603.
30. F. Lasne, L. Martin, N. Crepin, J. de Ceaurriz Detection of isoelectric profiles of erythropoietin in urine: Differentiation of natural and administered recombinant hormones. Anal. Biochem. 2002, 311, 119.
31. Pharmacia, in Isoelectric Focusing. Principles and Methods, Pharmacia Fine Chemicals, Uppsala, 1992, pp. 55.
32. GE Healthcare, DeStreak Rehydration Solution. Instructions 71-5025-42 AE, GE Healthcare, Uppsala, 2006, pp. 1-4.
33. GE Healthcare, Immobiline DryStrip pH 3-10, 7 cm. Instructions, GE Healthcare, Uppsala, 2005, pp. 1-8.
34. F. Lasne Double-blotting: A solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures. J. Immunol. Methods 2003, 276, 223.
35. O.J. Bjerrum, C. Schafer-Nielsen, in Electrophoresis '86, (Ed: M. J. Dunn ). Wiley-VCH, Weinheim, 1986, pp. 315-327.
36. A. Lim, C.A. Srebalus Barnes, in Protein and Peptide Mass Spectrometry in Drug Discovery, (Eds: M. L. Gross, G. Chen, B. N. Pramanik ). Wiley, Hoboken, 2012, pp. 287-320.
37. M.C. Janin-Bussat, J.M. Strub, W. Wagner-Rousset, O. Colas, C. Klinguer-Hamour, N. Corvaia, et al., in Antibody Engineering Vol. 1, (Eds: R. Kontermann, S. Dübel ). Springer, Berlin, 2010, pp. 613-634.
38. E. Harlow, D. Lane, Using Antibodies. A laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1999, pp. 74.
39. Thermo Scientific, Pierce Ig Binding Proteins (Protein A, G, A/G and L). Instructions, Thermo Scientific, Rockford, 2008, pp. 1-6.
40. Applied Biosystems, POROS A and G Perfusion Chromatography Columns for Protein A and G Affinity Chromatography. Operating Instructions, Applied Biosystems, Foster City, 2002, pp. 1-8.
41. Applied Biosystems, POROS MabCapture A Perfusion Chromatography Media. Protocol, Applied Biosystems, Foster City, 2007, pp. 1-16.
42. T. Thomas Labor und Diagnose. Indikation und Bewertung von Laborbefunden für die medizinische Diagnostik, 7th edition, TH-Books, Frankfurt, 2008, pp. 968.
43. B.O. Böhm, P. Kern, B. Neumeister, in Klinikleitfaden Labordiagnostik, 4th edition, (Eds: B. Neumeister, I. Besenthal, B. O. Böhm ). Urban & Fischer, München, 2009, pp. 418-421.
44. T. Miyake, C.K. Kung, E. Goldwasser Purification of human erythropoietin. J. Biol. Chem. 1977, 252, 5558.
45. J.L. Scaro, M. Carrera, C. Miranda, B. Martin, I. Torrejon A simple method for concentrating erythropoietin activity in plasma and in other body fluids. Acta Physiol. Pharmacol. Latinoam. 1988, 38, 363.
46. T. Van Maerken, A. Dhondt, J.R. Delanghe A rapid and simple assay to determine pegylated erythropoietin in human serum. J. Appl. Physiol. 2010, 108, 800.
47. F. Lasne, L. Martin, J. A. Martin A fast preparative method for detection of recombinant erythropoietin in blood samples. Drug Test. Anal. 2010, 2, 494.
48. M. Page, R. Thorpe, in The Protein Protocols Handbook, 2nd edition, (Ed: J.M. Walker ). Humana Press, Totowa, 2002, pp. 991.
49. M. Kohler, C. Ayotte, P. Desharnais, U. Flenker, S. Ludke, M. Thevis, et al. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int. J. Sports Med. 2008, 29, 1.
50. N. Leuenberger, S. Lamon, N. Robinson, S. Giraud, M. Saugy How to confirm C.E.R.A. doping in athletes' blood? Forensic Sci. Int. 2011, 213, 101.
51. I. Besenthal, B. Neumeister, in Klinikleitfaden Labordiagnostik, 4th edition, (Eds: B. Neumeister, I. Besenthal, B. O. Böhm ). Urban & Fischer, München, 2009, pp. 107.
52. K. Schriebl, E. Trummer, R. Weik, D. Muller, R. Kunert, C. Lattenmayer, et al. A novel strategy for quantitative isoform detection directly performed from culture supernatant. J. Pharm. Biomed. Anal. 2006, 42, 322.
53. K. Schriebl, E. Trummer, R. Weik, C. Lattenmayer, D. Muller, R. Kunert, et al. Applicability of different fluorescent dyes for isoform quantification on linear IPG gels. Electrophoresis 2007, 28, 2100.
54. I. Olsson, K. Larsson, R. Palmgren, B. Bjellqvist Organic disulfides as a means to generate streak-free two-dimensional maps with narrow range basic immobilized pH gradient strips as first dimension. Proteomics 2002, 2, 1630.
55. M. Corton, G. Villuendas, J.I. Botella, J.L. San Millan, H.F. Escobar-Morreale, B. Peral Improved resolution of the human adipose tissue proteome at alkaline and wide range pH by the addition of hydroxyethyl disulfide. Proteomics 2004, 4, 438.
56. C. Reichel Identification of zinc-alpha-2-glycoprotein binding to clone AE7A5 antihuman EPO antibody by means of nano-HPLC and high-resolution high-mass accuracy ESI-MS/MS. J. Mass Spectrom. 2008, 43, 916.